The worldwide market for prescription dermatological drugs exceeded $21 billion last year, according to a report from Kalorama Information. The market research firm said field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options available to physicians has expanded. Kalorama made its estimate in its latest report, World Market for Prescription Dermatological Drugs, 9th Edition (Anti-acne, Anti-aging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments).

Kalorama found that the worldwide market for prescription dermatological products reached $21.2 billion in 2015, growing at a rate of 7.9 percent from 2013 to 2015. The psoriasis and skin cancer treatments dermatology drug sectors were among those that showed dramatic gain in the last two years. Sales of prescription acne and rosacea and other drugs reflected a slower growth rate during this period because many of the drugs are older and have lost patent protection. Specific growth rates are detailed in Kalorama Information's report.

“The driving forces for this market include growth and aging of the worldwide population, new products and technologies, and focus on lifestyle treatments that improve the effects of aging and damage to the skin," said Bruce Carlson, Publisher of Kalorama Information.  

The report details the various categories of prescription dermatological drugs, describes the worldwide market for prescription dermatological drugs, and identifies major market factors that may help to shape the worldwide market for prescription dermatological drugs in the future. World Market for Prescription Dermatological Drugs, 9th Edition can be found at: http://www.kaloramainformation.com/redirect.asp?progid=87807&productid=9251725.